Ginkgo Bioworks (NYSE:DNA) shares are down following the company’s fourth-quarter and full-year 2025 financial report.

The stock’s decline comes as the company is focusing on investing in autonomous labs.

Divests Non-Core Business To Focus On Robotics

For the fourth quarter of 2025, Ginkgo Bioworks reported a strategic pivot towards robotics and AI, with CEO Jason Kelly emphasizing the company’s collaboration with the Department of Energy and OpenAI.

The company also announced plans to divest its biosecurity business to a consortium of investors for a minority stake, with the transaction expected to close in the first half of 2026, allowing Ginkgo to concentrate its resources on its autonomous labs initiative.

In addition, Ginkgo’s biosecurity business will operate as a standalone entity, aiming to enhance its growth potential with new investors.

This move is part of a broader strategy to capitalize on the increasing interest in defense technology and private capital markets, as stated by Kelly.

Ginkgo Bioworks Snapshot

A loss of $1.41 per share, missing the consensus loss of $1.36.

Sales of $33.32 million, down 24% year over year, ...